Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CytoSorbents Q4 2023 GAAP EPS $(0.12) Beats $(0.14) Estimate, Sales $8.700M Miss $9.285M Estimate

Author: Benzinga Newsdesk | March 14, 2024 05:00pm
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. The company reported quarterly sales of $8.700 million which missed the analyst consensus estimate of $9.285 million by 6.30 percent. This is a 7.36 percent decrease over sales of $9.391 million the same period last year.

Posted In: CTSO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist